Xtant Medical Holdings Inc ( (XTNT) ) has released its Q1 earnings. Here is a breakdown of the information Xtant Medical Holdings Inc presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Xtant Medical Holdings Inc. is a global medical technology company specializing in surgical solutions for spinal, orthopedic, and wound care disorders, offering a comprehensive portfolio of orthobiologics and spinal implant systems.
In its first quarter of 2025, Xtant Medical Holdings reported a significant 18% increase in revenue year-over-year, achieving positive net income and generating $1.3 million in operating cash flow. The company also raised its revenue guidance for the full year 2025.
Key financial highlights include a revenue of $32.9 million, a gross margin of 61.5%, and a net income of $58,000, marking a turnaround from a net loss in the previous year. The company also reported an adjusted EBITDA of $3.0 million, indicating improved operational efficiency. Recent strategic moves include the launch of Trivium™, a next-generation bone grafting product, and a secondary private sale of shares led by Nantahala Capital Management LLC.
Xtant Medical’s management expressed confidence in the company’s growth trajectory, citing the successful launch of Trivium™ and its potential to drive future growth. The company aims to expand its higher-margin orthobiologics portfolio, supported by positive feedback from surgeons and distribution partners.
Looking ahead, Xtant Medical remains optimistic about its growth prospects, with management emphasizing continued execution of strategic initiatives and expansion of its product offerings to enhance shareholder value.